Welcome to our dedicated page for Lumexa Imaging Holdings SEC filings (Ticker: LMRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lumexa Imaging is a nationwide provider of diagnostic imaging services and outpatient medical imaging, and its filings offer detailed insight into its capital structure, governance and material agreements.
Investors can review Lumexa’s registration statement and related documents associated with its initial public offering on the Nasdaq Global Select Market, as well as subsequent Current Reports on Form 8-K. For example, recent 8-K filings describe the completion of the IPO, the execution of an underwriting agreement and stockholders agreement, adoption of an Amended and Restated Certificate of Incorporation and Bylaws, and entry into indemnification agreements with directors and executive officers.
Another 8-K filing outlines an amended credit agreement that provides Lumexa Imaging subsidiaries with a secured term loan facility and a secured revolving credit facility. The filing details interest rate terms, maturities, restrictive covenants and a leverage-related financial covenant, along with guarantees and security interests from substantially all wholly owned subsidiaries, subject to specified exceptions. These disclosures help readers understand Lumexa’s borrowing arrangements and related obligations.
On this page, users can track Lumexa Imaging’s Forms 10-K and 10-Q when filed, along with additional 8-Ks, proxy statements and other submissions. Stock Titan enhances these documents with AI-powered summaries that explain key sections, highlight important covenants and capital structure details, and make lengthy filings more accessible. The platform also surfaces insider transaction reports on Form 4, enabling users to monitor equity transactions by Lumexa’s directors and executive officers in one place.
Lumexa Imaging Holdings, Inc. reported that its Chief Executive Officer and director received two equity awards on December 12, 2025 totaling 129,728 restricted stock units (RSUs), each RSU representing one share of common stock. Each grant covers 64,864 RSUs at an acquisition price of $0 per share.
The first 64,864 RSUs vest in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to the executive’s continued service. The second 64,864 RSUs vest in three substantially equal installments upon achieving stock price targets of $27.00, $36.00 and $45.00 per share, based on 60‑trading‑day volume weighted average prices over measurement periods that can extend to the fourth anniversary of the grant, also requiring continued service.
Lumexa Imaging Holdings, Inc. reported that a director acquired 27,027 restricted stock units, each representing the contingent right to receive one share of the company’s common stock, on December 12, 2025 at a price of $0 per unit.
Following this grant, the reporting person is shown as beneficially owning 27,027 shares of common stock. The RSUs will vest annually in three substantially equal installments on each of the first three anniversaries of the grant date, subject to the reporting person’s continued service with the company.
Lumexa Imaging Holdings, Inc. reported that a company director acquired 27,027 shares of common stock on 12/12/2025 through a restricted stock unit grant at a price of $0 per share. Following this grant, the director beneficially owns 27,027 shares held directly.
The award consists of restricted stock units, each representing the contingent right to receive one share of common stock. Of these units, 13,513 vested on the grant date, and the remaining units are scheduled to vest in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to the director’s continued service with the company.
Lumexa Imaging Holdings, Inc. reported that its Chief Medical Officer, as an officer of the company, acquired a total of 8,464 restricted stock units (RSUs) representing shares of common stock on 12/12/2025 at a price of $0 per share, resulting in beneficial ownership of 8,464 shares held directly.
One grant of 4,232 RSUs vests annually in three substantially equal installments on each of the first three anniversaries of the grant date, subject to continued service. A second grant of 4,232 RSUs vests in three substantially equal installments upon reaching stock price targets of $27.00, $36.00 and $45.00 per share, measured by the volume weighted average closing price over any 60 consecutive trading days within a period that begins after a 180-day lock-up and runs to the three-year anniversary, with unachieved targets remaining eligible to vest through the four-year anniversary.
Lumexa Imaging Holdings, Inc. reported insider equity activity for its Chief Legal Officer and Corporate Secretary, Julie Szeker, dated December 12, 2025. A transaction coded “M” involved 1,250,000 incentive units of Lumexa Imaging Equity Holdco, LLC tied to 66,182 shares of common stock, which, according to the footnotes, had been converted into stock at the closing of the company’s initial public offering with replacement awards subject to time- and performance-based vesting conditions.
Following the reported activity, Szeker directly beneficially owned 147,263 shares of common stock, including 11,876 shares that vest only if the stock reaches a volume-weighted average price of $24.97 over a 60-trading-day period after the IPO lock-up expires, subject to continued service. She also holds 81,081 restricted stock units, each representing one share of common stock, scheduled to vest in full on December 12, 2026, provided she continues serving the company.
Lumexa Imaging Holdings, Inc. executive Julie Szeker, the company’s Chief Legal Officer and Corporate Secretary, reported initial beneficial ownership of several equity awards linked to Lumexa common stock. She holds common units in Lumexa Imaging Equity Holdco, LLC that correspond to 12,617 shares of common stock that may be distributed after a 180‑day IPO lock‑up, plus incentive units corresponding to 66,182 shares, including 11,876 shares subject to performance-based vesting.
She also holds three stock option grants to purchase 41,665, 22,222 and 63,887 shares of common stock at an exercise price of $18.5 per share, each expiring in 2035. One option is fully vested, another vests in five annual installments starting February 8, 2023, and about 64.1% of the performance-based grant has vested, with the remainder vesting only if the stock achieves a volume‑weighted average price of $24.97 over 60 consecutive trading days after the IPO lock‑up period, while she continues in service.
Lumexa Imaging Holdings, Inc. disclosed stock option holdings for its Chief Medical Officer, who is an officer of the company. The filing shows two stock options, each giving the right to buy 194,444 shares of common stock at an exercise price of $18.5 per share, both expiring on 12/10/2035.
One option vests annually in five substantially equal installments starting from a vesting commencement date of August 1, 2025, conditioned on continued service. The other option vests in three substantially equal installments if the share price reaches targets of $27.00, $36.00, and $45.00 per share, based on the volume weighted average closing price over any consecutive 60 trading days after a 180-day lock-up period, also requiring continued service. The filing notes it was submitted late due to delays in receiving EDGAR codes.
Lumexa Imaging Holdings, Inc. completed its initial public offering, selling 25,000,000 shares of common stock at a price of $18.50 per share. The company plans to use the net proceeds to repay a portion of its borrowings under a secured term loan facility with Barclays Bank PLC and for working capital, capital expenditures and other general corporate purposes.
In connection with becoming a public company, Lumexa appointed four new directors to staggered board classes, entered into indemnification agreements with all directors and executive officers, and put into effect its amended and restated certificate of incorporation and bylaws, consistent with descriptions in its IPO prospectus.
Lumexa Imaging Holdings, Inc. reports the equity interests of a director and Chief Executive Officer in connection with their role at the company. The executive beneficially owns common units of Lumexa Imaging Equity Holdco, LLC that correspond to 14,948 shares of Lumexa’s common stock, which may be received after the closing of the company’s IPO when Lumexa Imaging Equity Holdco, LLC is permitted to distribute shares following a 180-day lock-up period.
The disclosure also lists two stock option awards, each covering 833,333 shares of common stock at an exercise price of $18.5 per share, expiring on 12/10/2035. One option vests in five substantially equal annual installments beginning on January 1, 2025, while the other vests in three equal tranches upon achieving volume-weighted average price targets of $27.00, $36.00 and $45.00 per share over any consecutive 60-trading-day period after the 180-day IPO lock-up, in each case subject to the executive’s continued service with the issuer.
Lumexa Imaging Holdings, Inc. disclosed that one of its directors holds a stock option covering 422,222 shares of common stock at an exercise price of $18.5 per share. This statement reflects the director’s beneficial ownership as a single reporting person.
According to the filing, 222,222 shares underlying the option have already vested. The remaining shares will vest in three substantially equal installments on November 27 of 2026, 2027 and 2028, and each installment depends on the director continuing to provide service to the company. This structure ties a large portion of the director’s potential equity interest to ongoing tenure with Lumexa Imaging.